-
1.发明公开公开(公告)号：US20240360209A1
公开(公告)日：2024-10-31
申请号：US18623647
申请日：2024-04-01
发明人： Bongcheol KIM , Wonkyum KIM , Jeongwon YOON , Junho CHUNG , Junyeong JIN , Eunhwoi YOU
IPC分类号： C07K16/24 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/68 , A61P25/00 , A61P25/02 , A61P29/00 , A61P35/00
CPC分类号： C07K16/24 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61P25/00 , A61P25/02 , A61P29/00 , A61P35/00 , A61K2039/505 , C07K2317/33 , C07K2317/41 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.
-
2.发明公开公开(公告)号：US20240182555A1
公开(公告)日：2024-06-06
申请号：US18360143
申请日：2023-07-27
发明人： Bongcheol KIM , Dong Sik KIM , Soon-gu KWON
IPC分类号： C07K16/24
CPC分类号： C07K16/24 , C07K2317/565 , C07K2317/622 , C07K2317/76
摘要： The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
-
3.发明授权公开(公告)号：US11746149B2
公开(公告)日：2023-09-05
申请号：US16626630
申请日：2018-06-27
发明人： Bongcheol Kim , Dong Sik Kim , Soon-gu Kwon
IPC分类号： A61K39/395 , A61K39/00 , C07K16/24
CPC分类号： C07K16/24 , C07K2317/565 , C07K2317/622 , C07K2317/76
摘要： The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a glaucoma in a subject in need thereof.
-
公开(公告)号：US11634484B2
公开(公告)日：2023-04-25
申请号：US17050056
申请日：2019-04-24
发明人： Bongcheol Kim , Dong Sik Kim , Soon-Gu Kwon
摘要： The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
-
公开(公告)号：US20220242910A1
公开(公告)日：2022-08-04
申请号：US17579463
申请日：2022-01-19
发明人： Jae Young SEONG , Jong-Ik HWANG , Dong-Hoon KIM , Gi Hoon SON , Yoo-Na LEE , Seongsik YUN , Arfaxad REYES-ALCARAZ
IPC分类号： C07K7/08 , A61P25/28 , A61P25/30 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/06 , A61K9/00 , A61K9/19
摘要： The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
-
公开(公告)号：US20220073601A1
公开(公告)日：2022-03-10
申请号：US17475214
申请日：2021-09-14
发明人： Bongcheol KIM , Jae-Keun LEE , Dong Sik KIM
摘要： The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
-
公开(公告)号：US12077579B2
公开(公告)日：2024-09-03
申请号：US17475214
申请日：2021-09-14
发明人： Bongcheol Kim , Jae-Keun Lee , Dong Sik Kim
CPC分类号： C07K16/24 , G01N33/6863 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要： The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
-
公开(公告)号：US20240166735A1
公开(公告)日：2024-05-23
申请号：US18350287
申请日：2023-07-11
发明人： Jae Young SEONG , Jong Ik HWANG , Woong SUN , Eun Bee CHO , Won-Ki KIM
IPC分类号： C07K16/24 , A61K38/17 , A61K48/00 , C07K14/47 , C07K16/18 , C12N15/113 , C12Q1/6886 , G01N33/577 , G01N33/68 , A61K39/00
CPC分类号： C07K16/24 , A61K38/1709 , A61K48/00 , C07K14/4701 , C07K14/4702 , C07K16/18 , C12N15/113 , C12Q1/6886 , G01N33/577 , G01N33/6896 , A61K2039/505 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C12N2310/11 , C12N2310/141 , C12Q2600/156 , G01N2333/47
摘要： The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
-
9.发明公开公开(公告)号：US20230357378A1
公开(公告)日：2023-11-09
申请号：US18301803
申请日：2023-04-17
发明人： Bongcheol KIM , Dong Sik KIM , Soon-gu KWON
摘要： The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.
-
公开(公告)号：US11560425B2
公开(公告)日：2023-01-24
申请号：US16626625
申请日：2018-06-27
发明人： Bongcheol Kim , Eun Bee Cho , Dong Sik Kim , Jae-Keun Lee , Soon-gu Kwon , Jae Young Seong , Juwon Shim , Tae Woo Kim , Shin-hyuk Kang
摘要： The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.023 秒)
